Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
The curriculum has been curated for General Physicians working in Clinikk
Surgical treatment of chronic pancreatitis is challenging in children and especially laparoscopic surgery has been rarely reported, worldwide
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
This new fund is amongst the largest for the sector in India
Wearable patch sensors (smart patches) are rising in popularity, as they offer a wide range of options for medical diagnosis
Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program
The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12
AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
Subscribe To Our Newsletter & Stay Updated
